Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
BeiGene heads for profit milestone after hemorrhaging cash
With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
Innovent ditches low-value stake sale after investor outcry
The biopharmaceutical company had planned to sell a 20% stake in its international unit to the group’s founder, but the cheap price sparked a crisis of market confidence Key Takeaways:…
BRIEF: BeiGene executive reportedly detained in AstraZeneca investigation
Yin Min, chief business officer for Greater China at innovative drugmaker BeiGene Ltd. (BGNE.US; 6160.HK; 688235.SH), has been detained as part of an investigation unrelated to the company’s operations, according…
Junshi narrows its losses but delivers no cure for share price woes
The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum…
BeiGene’s aggressive expansion brings revenue jolt
The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year Key…
BeiGene still bleeding red ink despite blockbuster drug
The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
Recent Articles
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK
ONC.US
688235.SHG
Junshi narrows its losses but delivers no cure for share price woes
1877.HK
688180.SHG
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US
6160.HK
688235.SHG
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US
6160.HK
688235.SHG
RELATED ARTICLES
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG -
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Innogen Pharma jostles for a slice of the weight-loss market
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
